Baked Bean Recall Update as FDA Sets Highest Risk Level
The Food and Drug Administration (FDA) has issued a Class I recall—the highest risk level—for Yellowstone Brown Sugar Molasses Baked Beans.
Vietti Food Group of Nashville recalled 4,515 cases from shelves in 23 states after it was found that cans, mislabeled as the Brown Sugar Molasses variety, instead contained Beef and BBQ Baked Beans with undeclared soy, putting allergy sufferers at risk.
Newsweek has contacted the Vietti Food Group outside of regular working hours via email for comment.
The FDA's Class I designation applies to recalls where there is a reasonable chance a product could cause serious health consequences or death. An undeclared allergen such as soy poses a life-threatening danger for those with allergies and points to the critical importance of food labeling. Expansive distribution of these beans amplifies risk for families and individuals across the U.S.
The recall affects Yellowstone Brown Sugar Molasses Baked Beans in 15-ounce cans, identified by UPC 071846187071 and labeled with a best if used by date of February 17, 2028, on the bottom of each can.
Vietti Food Group initiated the recall voluntarily on May 2, and the FDA assigned a Class I classification to this recall on May 16, 2025.
Class I recalls are reserved for the most severe cases, where there is a credible threat of serious health consequences or death. In this instance, the risk comes from consumption of an allergen (soy) by unsuspecting individuals who rely on label accuracy for health management.
The recalled baked beans were distributed to retail outlets in the following states: Arizona, Colorado, Delaware, Florida, Georgia, Illinois, Iowa, Kansas, Kentucky, Louisiana, Michigan, Mississippi, Missouri, New Hampshire, New York, North Carolina, Ohio, Oregon, Pennsylvania, Tennessee, Texas, Utah, and Virginia.
Consumers in these states who purchased the product with the recalled lot code were advised to check their pantries and return affected cans for a full refund.
No illnesses or adverse reactions had been reported as of the last FDA update.
The FDA said on its website: "Food allergic reactions vary in severity from mild symptoms involving hives and lip swelling to severe, life-threatening symptoms, often called anaphylaxis, that may involve fatal respiratory problems and shock.
"While promising prevention and therapeutic strategies are being developed, food allergies currently cannot be cured. Early recognition and learning how to manage food allergies, including which foods to avoid, are important measures to prevent serious health consequences."
It added: "To protect those with food allergies and other food hypersensitivities, the FDA enforces regulations requiring companies to list ingredients on packaged foods and beverages. For certain foods or substances that cause allergies or other hypersensitivity reactions, there are more specific labeling requirements."
The recall remains ongoing, pending further updates from the FDA. Consumers who have purchased the affected canned beans are urged not to consume the product if they have a soy allergy or sensitivity. Instead, they should return it to the place of purchase to receive a full refund. For further assistance, Vietti Food Group is available at (513) 682-2474 weekdays from 8:00 a.m. to 4:00 p.m. CT or by email at recall@zwanfood.com
Related Articles
Ice Cream Recalled Nationwide: Full List of Products AffectedTomatoes Recalled in 14 States as FDA Sets Highest Risk LevelWalmart Products Recalled Nationwide: Full List of Items ImpactedYogurt Recall Sparks Nationwide Warning
2025 NEWSWEEK DIGITAL LLC.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
YolTech Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for YOLT-101, an In Vivo Base Editing Therapy to Treat Heterozygous Familial Hypercholesterolemia (HeFH)
SHANGHAI, June 5, 2025 /PRNewswire/ -- YolTech Therapeutics, a clinical-stage biotechnology company developing in vivo genome editing therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for YOLT-101, an in vivo base editing therapy targeting PCSK9 for the treatment of heterozygous familial hypercholesterolemia (HeFH). "The FDA IND clearance marks a significant milestone for YolTech," said Dr. Yuxuan Wu, Co-founder and CEO of YolTech Therapeutics. "In vivo gene editing represents a new generation of therapeutics—offering one-time, durable solutions for chronic and genetic diseases. We are committed to advancing breakthrough gene editing solutions that offer transformative benefits for patients living with severe genetic and cardiovascular diseases. '' About YOLT-101 YOLT-101 is an investigational in vivo base editing therapy designed to be a single-dose treatment to durably reduce blood LDL-C. It is based on YolTech's proprietary adenine base editor, YolBE—specifically hpABE5—which comprises nCas and a novel deaminase evolved from Hafnia paralvei. For delivery, YOLT-101 utilizes YolTech's innovative lipid nanoparticle (LNP) delivery system. Unlike traditional CRISPR/Cas9 systems that rely on DNA double-strand breaks (DSBs), hpABE5 enables precise A•T to G•C base conversion without introducing DSBs, thereby significantly reducing risks of chromosomal abnormalities and off-target effects. YOLT-101 is being evaluated in ongoing investigator-initiated trial (IIT), where it has demonstrated a favorable safety profile and robust LDL-C–lowering effects. For detailed clinical data, please refer to: About Familial Hypercholesterolemia (FH) Familial hypercholesterolemia (FH) is caused by mutations in LDL metabolism-related genes such as LDLR, APOB, and PCSK9. Patients with FH exhibit significantly elevated levels of low-density lipoprotein cholesterol (LDL-C) and a high risk of early-onset atherosclerotic cardiovascular disease (ASCVD). The estimated global prevalence of FH is 1 in 200 to 1 in 250, affecting approximately 34 million individuals worldwide. Current treatment strategies—lifestyle modifications, statins, ezetimibe, PCSK9 inhibitors, lipoprotein apheresis, and even liver transplantation—often fall short in terms of efficacy, tolerability, or patient adherence. This creates a critical unmet need for durable, one-time therapies that can address the root cause of disease. About YolTech YolTech Therapeutics is a clinical-stage in vivo gene editing company committed to pioneering the next generation of precision genetic medicines. Our approach combines innovative gene editing technologies with an advanced lipid nanoparticle (LNP) delivery system, creating a versatile platform designed to address a wide range of serious diseases. Central to our mission is the development of internal capabilities, including end-to-end manufacturing, to ensure the highest standards of quality and scalability. Our lead candidate, targeting ATTR, marks a significant milestone as China's first LNP-mediated in vivo gene editing therapy to enter clinical development. With promising early clinical outcomes, YolTech is also advancing therapies for familial hypercholesterolemia (FH) and primary hyperoxaluria type 1 (PH1). As a company dedicated to transforming the treatment landscape, YolTech continues to push the boundaries of what is possible in gene editing. To learn more, please visit: View original content: SOURCE YolTech Therapeutics Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
YolTech Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for YOLT-101, an In Vivo Base Editing Therapy to Treat Heterozygous Familial Hypercholesterolemia (HeFH)
SHANGHAI, June 5, 2025 /PRNewswire/ -- YolTech Therapeutics, a clinical-stage biotechnology company developing in vivo genome editing therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for YOLT-101, an in vivo base editing therapy targeting PCSK9 for the treatment of heterozygous familial hypercholesterolemia (HeFH). "The FDA IND clearance marks a significant milestone for YolTech," said Dr. Yuxuan Wu, Co-founder and CEO of YolTech Therapeutics. "In vivo gene editing represents a new generation of therapeutics—offering one-time, durable solutions for chronic and genetic diseases. We are committed to advancing breakthrough gene editing solutions that offer transformative benefits for patients living with severe genetic and cardiovascular diseases. '' About YOLT-101 YOLT-101 is an investigational in vivo base editing therapy designed to be a single-dose treatment to durably reduce blood LDL-C. It is based on YolTech's proprietary adenine base editor, YolBE—specifically hpABE5—which comprises nCas and a novel deaminase evolved from Hafnia paralvei. For delivery, YOLT-101 utilizes YolTech's innovative lipid nanoparticle (LNP) delivery system. Unlike traditional CRISPR/Cas9 systems that rely on DNA double-strand breaks (DSBs), hpABE5 enables precise A•T to G•C base conversion without introducing DSBs, thereby significantly reducing risks of chromosomal abnormalities and off-target effects. YOLT-101 is being evaluated in ongoing investigator-initiated trial (IIT), where it has demonstrated a favorable safety profile and robust LDL-C–lowering effects. For detailed clinical data, please refer to: About Familial Hypercholesterolemia (FH) Familial hypercholesterolemia (FH) is caused by mutations in LDL metabolism-related genes such as LDLR, APOB, and PCSK9. Patients with FH exhibit significantly elevated levels of low-density lipoprotein cholesterol (LDL-C) and a high risk of early-onset atherosclerotic cardiovascular disease (ASCVD). The estimated global prevalence of FH is 1 in 200 to 1 in 250, affecting approximately 34 million individuals worldwide. Current treatment strategies—lifestyle modifications, statins, ezetimibe, PCSK9 inhibitors, lipoprotein apheresis, and even liver transplantation—often fall short in terms of efficacy, tolerability, or patient adherence. This creates a critical unmet need for durable, one-time therapies that can address the root cause of disease. About YolTech YolTech Therapeutics is a clinical-stage in vivo gene editing company committed to pioneering the next generation of precision genetic medicines. Our approach combines innovative gene editing technologies with an advanced lipid nanoparticle (LNP) delivery system, creating a versatile platform designed to address a wide range of serious diseases. Central to our mission is the development of internal capabilities, including end-to-end manufacturing, to ensure the highest standards of quality and scalability. Our lead candidate, targeting ATTR, marks a significant milestone as China's first LNP-mediated in vivo gene editing therapy to enter clinical development. With promising early clinical outcomes, YolTech is also advancing therapies for familial hypercholesterolemia (FH) and primary hyperoxaluria type 1 (PH1). As a company dedicated to transforming the treatment landscape, YolTech continues to push the boundaries of what is possible in gene editing. To learn more, please visit: View original content: SOURCE YolTech Therapeutics
Yahoo
6 hours ago
- Yahoo
Oral health continues to be a challenge in Arkansas
LITTLE ROCK, Ark. – Brushing, flossing and annual dental checkups are very important, but officials say oral care in Arkansas continues to be a problem. Officials with the ADH Oral Health Program said Arkansas has many rural areas, and access to oral health care for people who live in rural areas can be challenging due to longer driving distances to care and other factors such as insurance coverage. Arkansas also has some counties that have been federally designated as dental provider shortage areas, which means there are not enough dentists to care for the population residing in the county. FDA Signals major shift on fluoride treatments for children Dental Director for Delta Dental of Arkansas, a dental benefits company, Niki Carter says after and during COVID oral health care became bad nationwide. However, last year Arkansas was ranked low for poor oral care. 'Arkansas is 50th in the nation, so we have our work cut for us,' Carter said. Carter explained that one way there's a gap in care has to do with distribution. '60% of dentists practice in only eight of the state's 75 counties and these eight counties represent 40% of the state's population that are all in urban areas,' Carter said. 'Technically, 60% of the population lives in rural areas.' Carter said that's not the only problem, the other issue is a shortage of dentists. 'Technically, there is a shortage of dentists per 100,000 population in our state,' Carter said. Study ranks Arkansas at the absolute bottom for dental health Carter says most dentists want to practice in metropolitan areas, which is why she's glad Lyon College will open the state's first dental school this month. 'One aspect of poor oral health is it affects numerous systemic illnesses,' Carter said. She also says students could go through a loan repayment program helping serve those needed areas. 'New dental students are graduating with $300,000 and $400,000 in debt. Through the repayment program, they will go to these rural areas and practice for a certain amount of time and pay back that loan,' Carter said. Carter says they also partner with multiple companies that provide care to patients, hoping they can help close the gap. One of the partners is Teledentistry, where members have 24/7 access to dental visits. Lyon College holds groundbreaking for first dental school in Arkansas Officials with the Arkansas Department of Health Office of Oral Health also say they're focused on promoting lifelong, optimum oral health for all Arkansans through education and prevention. This includes programming that educates health care providers about the interplay of oral health on systemic health, raising awareness about oral disease and the importance of regular dental care and programming that promotes and supports daily oral health hygiene habits for all ages, particularly children. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.